1. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial
- Author
-
Arsene Mekinian, David Saadoun, Eric Vicaut, Sara Thietart, Bertrand Lioger, Patrick Jego, Alexandre Bleibtreu, Nicolas Limal, Jerome Connault, Jacques-Eric Gottenberg, Pauline Lhorte, Jean Pierre Bertola, Juliette Delforge, Nicole Ferreira-Maldent, Antoinette Perlat, Zohra Talib, Matthieu Vautier, Léa Savey, Isabelle Quiere, Patrice Cacoub, Olivier Fain, and for the French Takayasu network
- Subjects
Takayasu arteritis ,Tocilizumab ,Vasculitis treatment ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Objectives To assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK). Methods Prospective open-labeled trial in naïve patients with TAK who received steroids at the dose of 0.7 mg/kg/day and 7 infusions of 8 mg/kg/month of tocilizumab. The primary endpoint was the number of patients who discontinued steroids after 7 infusions of tocilizumab. Secondary endpoints included disease activity and the number of relapses during 18-month follow-up. Results Thirteen patients with TAK were included, with a median age of 32 years [19–45] and 12 (92%) females. Six (54%) patients met the primary end-point. A significant decrease of disease activity was observed after 6 months of tocilizumab therapy: decrease of median NIH scale (3 [3, 4] at baseline, versus 1 [0–2] after 6 months; p
- Published
- 2020
- Full Text
- View/download PDF